Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 2258

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 9
Chunk 2258
---

  
    Exercisable as of March 31, 2025 
     1,905,000  
    $5.50  
     7.1  
    $- 

As of March 31, 2025,
the Company had unrecognized stock-based compensation expense for the stock options in the 2021 BC Plan of approximately $2.2
million which is expected to be expensed over the weighted average remaining service period of 1.3
years. For the year ended March 31, 2024, the weighted
average fair value of options granted was $4.60 per share. There were no grants in the year ended March 31, 2025.

On September 7, 2023, Beyond
Cancer’s Board of Directors approved a modification to the exercise prices of all previously issued options to $5.50
per share. Stock compensation costs associated with the share re-price is de minimis.

The Company’s 2023 NeuroNos Ltd. Equity Incentive
Plan (the “2023 NNOS Plan”) allows for awards to officers, directors, employees, and consultants of stock options, restricted
stock units and restricted shares of NeuroNos Ltd.’s common stock. The vesting terms of the options issued under the 2025 NNOS Plan
are generally four years and they expire ten years from the grant date. On March 31, 2025, the Company’s Board of Directors approved
to reserve for issuance 1,275,000 shares of common stock. As of March 31, 2025, 50,861 shares were available under the 2023 NNOS Plan.

A summary of the change in stock options for NeuroNos
for the year ended March 31, 2025 is as follows:

 SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS

    Number Of Options  
    Weighted Average Exercise Price–- Options  
    Weighted Average Remaining Contractual Life-  Options  
    Aggregate Intrinsic Value (thousands) 

    Granted 
     1,224,139  
    $0.14  
     -  
     - 
  
    Exercised 
     -  
     -  
     -  
     - 
  
    Forfeited 
     -  
     -  
     -  
                 - 
  
    Options outstanding as